Skip to main content

Table 4 Treatment-emergent adverse events occurring in ≥ 5% of patients in the overall period (SAF)

From: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

 Total (N = 843)
n (%)
Nasopharyngitis335 (39.7)
Rheumatoid arthritis105 (12.5)
Herpes zoster99 (11.7)
Influenza80 (9.5)
Bronchitis68 (8.1)
Blood creatine phosphokinase increased66 (7.8)
Contusion59 (7.0)
Hypertension57 (6.8)
Pharyngitis56 (6.6)
Dental caries51 (6.0)
Upper respiratory tract infection51 (6.0)
Constipation49 (5.8)
Cystitis47 (5.6)
Gastroenteritis47 (5.6)
Back pain42 (5.0)
Cough42 (5.0)
  1. SAF safety analysis set